From the US to Shanghai: Daniel’s lung cancer treatment and intensive care

Seeking options after previous treatment

Daniel was an American patient in his seventies with advanced non-small cell lung cancer and Parkinson's disease. After standard treatment at MD Anderson Cancer Center, third-line treatment failed and fourth-line treatment also did not control progression.

In November 2025, his doctor suggested considering the Chinese-developed ivonescimab.

[2]

Contact through his children and video consultation

His two children, both doctors, contacted several institutions before Jiahui International Cancer Center. The initial consultation involved an oncologist, clinical pharmacist and case managers to assess medicine options and subsequent care arrangements.

The English hospital account states that a late-November video consultation was arranged within one week of first contact. The Chinese account says visas, travel and initiation of inpatient treatment were completed just over a week after the first video consultation.

[3][2]

Treatment in China: Critical reactions and care during treatment

After admission, he received ivonescimab to control the disease. Critical immune-related adverse reactions required ICU transfer. Oncology, neurology and intensive care teams managed them together, inviting lung cancer expert and principal ivonescimab investigator Zhou Caicun to advise.

Once stable, he returned to an ordinary ward for continued treatment.

[2][3]

Rehabilitation and communication with family overseas

Neurology also adjusted Parkinson's medicines, assessed fall risk and arranged rehabilitation. Care involved other illness management and daily function as well as lung cancer medicines.

When his children could not accompany him throughout, the team regularly updated family in the United States, arranged video consultations and brought other specialties into discussions as needed, allowing continued family participation in treatment decisions.

[2]

Status and follow-up at the time of reporting

An early-March 2026 English hospital account described stable disease after about two months of treatment, with ongoing care and follow-up. A 14 March interview further recorded discharge for follow-up. Stable disease does not mean the tumour has disappeared; these accounts do not establish long-term efficacy.

[3][1]